Ser339
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser339  -  CXCR4 (human)

Site Information
GkrGGHssVstEsEs   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 458320

In vivo Characterization
Methods used to characterize site in vivo:
flow cytometry ( 6 ) , mass spectrometry ( 5 , 10 , 11 , 12 , 13 , 14 , 16 , 17 , 18 , 19 ) , mutation of modification site ( 2 ) , phospho-antibody ( 3 , 4 , 6 , 7 , 8 , 9 , 14 , 15 , 20 ) , western blotting ( 3 , 4 , 6 , 7 , 8 , 9 , 14 , 15 )
Disease tissue studied:
leukemia ( 3 ) , chronic lymphocytic leukemia ( 6 ) , T cell leukemia ( 3 ) , lung cancer ( 9 ) , non-small cell lung cancer ( 9 ) , non-small cell lung adenocarcinoma ( 9 ) , non-small cell large cell lung carcinoma ( 9 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 2 , 14 ) , A549 (pulmonary) ( 9 ) , astrocyte ( 14 ) , B lymphocyte-blood ( 6 ) , D425 ( 8 ) , glial ( 20 ) , HCC827 (pulmonary) ( 9 ) , HeLa (cervical) ( 5 , 10 , 13 ) , Jurkat (T lymphocyte) ( 3 , 11 , 12 , 15 , 16 , 17 , 18 , 19 ) , LN428 (glial) ( 20 ) , mononuclear-blood ( 4 ) , myeloid-bone marrow ( 7 ) , NCI-H1299 (pulmonary) ( 9 ) , NCI-H460 (pulmonary) ( 9 ) , U87MG (glial) ( 20 )

Upstream Regulation
Regulatory protein:
CXCL12 (human) ( 3 ) , GRK5 (human) ( 8 ) , PPM1D (human) ( 8 ) , TSPAN3 (human) ( 7 )
Putative in vivo kinases:
GRK6 (mouse) ( 14 ) , Pim1 (human) ( 15 )
Treatments:
antibody ( 6 ) , CXCL12 ( 14 , 15 , 20 ) , EGF ( 5 , 20 ) , IL-24 ( 9 ) , K00486 ( 15 ) , phorbol_ester ( 15 , 20 ) , plerixafor ( 3 , 4 ) , siRNA ( 15 ) , X4-2-6 ( 3 )

Downstream Regulation
Effects of modification on CXCR4:
activity, induced ( 7 ) , intracellular localization ( 8 , 15 ) , receptor internalization, induced ( 3 )
Effects of modification on biological processes:
cell growth, induced ( 7 ) , cell growth, inhibited ( 8 )

References 

1

Kwon D, et al. (2022) Targeting refractory mantle cell lymphoma for imaging and therapy using C-X-C chemokine receptor type 4 radioligands. Clin Cancer Res
35078860   Curated Info

2

Luo J, et al. (2021) Characterization of a new WHIM syndrome mutant reveals mechanistic differences in regulation of the chemokine receptor CXCR4. J Biol Chem 298, 101551
34973340   Curated Info

3

Hitchinson B, et al. (2018) Biased antagonism of CXCR4 avoids antagonist tolerance. Sci Signal 11
30327409   Curated Info

4

Kremer KN, et al. (2017) TCR-CXCR4 signaling stabilizes cytokine mRNA transcripts via a PREX1-Rac1 pathway: implications for CTCL. Blood 130, 982-994
28694325   Curated Info

5

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

6

Saint-Georges S, et al. (2016) Protein kinase D-dependent CXCR4 down-regulation upon BCR triggering is linked to lymphadenopathy in chronic lymphocytic leukaemia. Oncotarget 7, 41031-41046
27127886   Curated Info

7

Kwon HY, et al. (2015) Tetraspanin 3 Is Required for the Development and Propagation of Acute Myelogenous Leukemia. Cell Stem Cell 17, 152-64
26212080   Curated Info

8

Buss MC, et al. (2015) The WIP1 oncogene promotes progression and invasion of aggressive medulloblastoma variants. Oncogene 34, 1126-40
24632620   Curated Info

9

Panneerselvam J, et al. (2015) IL-24 Inhibits Lung Cancer Cell Migration and Invasion by Disrupting The SDF-1/CXCR4 Signaling Axis. PLoS One 10, e0122439
25775124   Curated Info

10

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

11

Guo A (2011) CST Curation Set: 12074; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

12

Guo A (2011) CST Curation Set: 11849; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTDXEAntibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CK2 Substrate (P-S/T3-100) Rabbit mAb Cat#: 8738
Curated Info

13

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

14

Busillo JM, et al. (2010) Site-specific Phosphorylation of CXCR4 Is Dynamically Regulated by Multiple Kinases and Results in Differential Modulation of CXCR4 Signaling. J Biol Chem 285, 7805-17
20048153   Curated Info

15

Grundler R, et al. (2009) Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J Exp Med 206, 1957-70
19687226   Curated Info

16

Possemato A (2009) CST Curation Set: 6384; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XXp[ST]
Curated Info

17

Possemato A (2008) CST Curation Set: 5273; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

18

Stokes M (2008) CST Curation Set: 3885; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

19

Possemato A (2007) CST Curation Set: 2926; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](D/E)X(D/E) Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CK2 Substrate (P-S/T3-100) Rabbit mAb Cat#: 8738
Curated Info

20

Woerner BM, et al. (2005) Widespread CXCR4 activation in astrocytomas revealed by phospho-CXCR4-specific antibodies. Cancer Res 65, 11392-9
16357147   Curated Info